11.10.22 | SITC
TNG260, a CoREST-selective deacetylase inhibitor, reverses anti-PD1 resistance driven by loss of STK11
In vivo CRISPR screens identify HDAC1 as an immune sensitizer reversing immune resistance driven by STK11 loss
Whole genome CRISPR-Cas9 screens in a cancer cell line panel co-cultured with antigen-specific cytotoxic CD8 T cells are a powerful engine for immuno-oncology drug target discovery
Leveraging CRISPR-Cas9 screening platform for discovery of novel tumor intrinsic phagocytosis modulators